Australia
· Delayed Price · Currency is AUD Amplia Therapeutics Company Description
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial.
It also develops AMP886, which is in preclinical trial for treating solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018.
Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
| Country | Australia |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Christopher Burns |
Contact Details
Address: 350 Queen Street Melbourne, 3000 Australia | |
| Phone | 61 3 9123 1140 |
| Website | ampliatx.com |
Stock Details
| Ticker Symbol | ATX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | April - March |
| Reporting Currency | AUD |
| ISIN Number | AU0000023822 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. | Chief Executive Officer, MD and Director |
| Timothy Luscombe B.Com., C.A. | Chief Financial Officer |
| Rhiannon Jones B.Sc., Ph.D. | Chief Operating Officer |
| Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD | Company Secretary |